Betaferon 250 microgram/ml

DRUG3 trials

Sponsors

Antwerp University Hospital, Novartis Pharma AG, Les Hopitaux Universitaires De Strasbourg

Conditions

Multiple SclerosisProgressive Multiple Sclerosisrelapsing multiple sclerosis (RMS)

Phase 2

Metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration: a phase IIb triple-blind placebo-controlled randomized clinical trial (MACSiMiSE-BRAIN)

Active, not recruitingCTIS2023-503190-38-00

Antwerp University HospitalProgressive Multiple Sclerosis

Start: 2023-11-23Target: 120Updated: 2025-11-07

Phase 3

An Open-Label, Rater-Blind, Randomized, Multi-Center, Parallel-Arm, Active-Comparator Study to Assess the Efficacy and Tolerability of Ofatumumab 20mg SC monthly vs. First Line DMT - physician’s choice in the treatment of newly diagnosed RMS (STHENOS)

CompletedCTIS2023-507431-37-00

Novartis Pharma AGrelapsing multiple sclerosis (RMS)

Start: 2021-07-23End: 2025-11-04Target: 186Updated: 2025-06-02

DISEASE MODIFYING THERAPIES WITHDRAWAL IN INACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS PATIENTS AGED 55 AND OVER: A MULTICENTRIC, RANDOMIZED, CONTROLLED, OPEN-LABEL CLINICAL TRIAL - TWINS

RecruitingCTIS2024-513475-41-00

Les Hopitaux Universitaires De StrasbourgMultiple Sclerosis

Start: 2025-02-03Target: 200Updated: 2024-11-08

Related Papers

A metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration (MACSiMiSE-BRAIN): study protocol for a multi-center randomized placebo controlled clinical trial

Frontiers in Immunology2024-02-2123 citations